The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

adorial.com

Stage

Acquired | Acquired

Valuation

$0000 

About Adorial

Adorial is a virtual drug discovery company using a proprietary silico genomics platform to identify novel drug targets.

Adorial Headquarter Location

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Adorial

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Adorial is included in 1 Expert Collection, including Omics.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest Adorial News

C4X Discovery acquires Adorial Pharma

Apr 27, 2016

27 April 2016 Manchester-headquartered drug researcher C4X Discovery has acquired the developer of a mathematical tool that identifies the causes of disease that can be targeted by pharmaceuticals. C4X has bought Adorial Pharma, the developer of Taxonomy3. Both businesses were funded by Innovate UK. Adorial's technology, which is based on novel mathematics, analyses publicly available genetic datasets generated across broad therapeutic areas and is able to mine more genetic insights than conventional methods. This can lead to the discovery and validation of novel drug targets with direct genetic support, which is known to increase the probability of successful drug launch. Dr Clive Dix, executive chairman of C4X Discovery, said: "With Adorial, we now not only have the ability to create the best-in-class molecules against any known therapeutic target using C4XD's approach to ligand-based drug discovery, but also the ability to identify our own highly relevant and unique targets using Taxonomy3. " Dr Alun McCarthy, former chief executive of Adorial and now vice-president of novel target biology and genomics at C4X, said: "The combination of Adorial's ability to identify novel drug targets with C4X's ability to rapidly generate molecules against these targets creates an extremely powerful drug discovery engine. " Adorial was founded by Dr McCarthy and his colleague Dr Olivier Delrieu and was a spin-out in 2014 from drug discovery company PGXIS.

  • What is Adorial's latest funding round?

    Adorial's latest funding round is Acquired.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.